| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Macdonald S: Aspirin use to be banned in under 16 year olds. BMJ. 2002 Nov 2;325(7371):988. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12411346 # Sneader W: The discovery of aspirin: a reappraisal. BMJ. 2000 Dec 23-30;321(7276):1591-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11124191 # Aukerman G, Knutson D, Miser WF: Management of the acute migraine headache. Am Fam Physician. 2002 Dec 1;66(11):2123-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12484694 # Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988 Aug 13;2(8607):349-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2899772 # Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS: Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007 May;41(5):737-41. Epub 2007 Apr 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17456544 (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| - The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours. (en)
|
| http://linked.open...ugbank/indication
| - For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| - Acetylsalicylic acid (en)
|
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - The analgesic, antipyretic, and anti-inflammatory effects of acetylsalicylic acid are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Acetylsalicylic acid directly and irreversibly inhibits the activity of both types of cyclooxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes acetylsalicylic acid different from other NSAIDS (such as diclofenac and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Acetylsalicylic acid's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation-inhibiting effect of acetylsalicylic acid specifically involves the compound's ability to act as an acetyl donor to cyclooxygenase; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Irreversible acetylation renders cyclooxygenase inactive, thereby preventing the formation of the aggregating agent thromboxane A2 in platelets. Since platelets lack the ability to synthesize new proteins, the effects persist for the life of the exposed platelets (7-10 days). Acetylsalicylic acid may also inhibit production of the platelet aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel endothelial cells; however, inhibition prostacyclin production is not permanent as endothelial cells can produce more cyclooxygenase to replace the non-functional enzyme. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open.../drugbank/synonym
| - Acetylsalicylic acid (en)
- Aspirin (en)
- Easprin (en)
- Polopiryna (en)
- 2-Acetoxybenzenecarboxylic acid (en)
- 2-Acetoxybenzoic acid (en)
- ASA (en)
- Acetylsalicylate (en)
- Acidum acetylsalicylicum (en)
- Salicylic acid acetate (en)
- 2-(ACETYLOXY)benzoic acid (en)
- Acetylsalicylsaeure (en)
- Acide 2-(acetyloxy)benzoique (en)
- Acide acétylsalicylique (en)
- Azetylsalizylsaeure (en)
- Azetylsalizylsäure (en)
- O-acetylsalicylic acid (en)
- o-acetoxybenzoic acid (en)
- o-carboxyphenyl acetate (en)
- ácido acetilsalicílico (en)
|
| http://linked.open...drugbank/toxicity
| - Oral, mouse: LD<sub>50</sub> = 250 mg/kg; Oral, rabbit: LD<sub>50</sub> = 1010 mg/kg; Oral, rat: LD<sub>50</sub> = 200 mg/kg. Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia, hypotension, hallucination, renal failure, confusion, seizure, coma, and death. (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open...k/foodInteraction
| - Avoid alcohol, alcohol appears to cause a 50 to 100% increases in ASA serum levels. (en)
- Take with a full glass of water. (en)
- Take with food to reduce gastric irritation. (en)
|
| http://linked.open.../drugbank/mixture
| |
| http://linked.open...nk/proteinBinding
| - High (99.5%) to albumin. Decreases as plasma salicylate concentration increases, with reduced plasma albumin concentration or renal dysfunction, and during pregnancy. (en)
|
| http://linked.open...ynthesisReference
| - Marino Gobetti, Guido Vandoni, "Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them." U.S. Patent US4563443, issued March, 1981. (en)
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)